Skip to content

PolitiKit

Lobbying by Innovative Medicines Canada: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Organization

Innovative Medicines Canada

Meetings this Parliament
98
With MPs
37
Since Nov 2021
279
Active registrations
1

Most recent reported meeting: Sep 18, 2026.

Registrations in effect

In-house (organization) In effect since Sep 11, 2026

Filed by Bettina Hamelin, President and CEO

Lobbyists

  • Patricia Best · Vice-President, Government and Stakeholder Relations Former designated public office holder

    Formerly Senior Special Advisor, Office of the Minister of Finance, Minister of Finance (2014–2015)

    Formerly Director of Communications, Minister's Office - Natural Resources Canada, Minister of National Resources Canada (2011–2012)

  • Agata Stankiewicz · Senior Director, Government Relations, Ontario Former public office holder

    Formerly Trade Commissioner, Toronto Office, Global Affairs Canada (2018–2018)

    Formerly Policy Analyst, Office of International Affairs for the Health Portfolio, Public Health Agency of Canada (2016–2018)

    Formerly Policy Analyst, Social Determinants and Science Integration Directorate, Public Health Agency of Canada (2012–2016)

    Formerly Epidemiologist, Centre for Chronic Disease Prevention, Public Health Agency of Canada (2010–2012)

  • Bettina Hamelin · President and CEO Former public office holder

    Formerly Vice President, Research Partnerships, Natural Sciences and Engineering Research Council of Canada, Council of Canada (2015–2017)

  • Brendan Lounsbery · General Counsel & Vice President, Legal, Compliance & Regulatory
  • Charles Brown · Director, Government Affairs, West Former public office holder

    Formerly Labour Market Economic Analyst, Economic Services, Employment and Immigration Canada (1989–1992)

  • Greg Hein · Vice President, Strategy, Systems Transformation & Research
  • Hugh Scott · Executive Director, Strategic Alliances Former public office holder

    Formerly Legislative Assistant to Albina Guarnieri, M.P. - Parliamentary Secretary to the Minister of Canadian Heritage, Parliament Hill Office, Canadian Heritage (1994–1998)

  • Jennifer Buckley · Senior Director, Regulatory Affairs and Clinical Research Transformation
  • Joe Farago · Executive Director, Market Access
  • Kristian LeBlanc · Senior Director, Atlantic, Government Relations
  • Michael Dietrich · Vice President, Market Access Policy Former public office holder

    Formerly Jr. Research Analyst, Industrial Analysis, Industry Canada (2004–2004)

  • Sophie Normand · Director, Federal Government Relations Former public office holder

    Formerly Social Media Coordinator, Communications Directorate, Senate of Canada (2020–2021)

    Formerly Social Media and Special Projects Coordinator, Office of the Speaker of the House of Commons, Parliament of Canada (2018–2019)

    Formerly Director of Events (acting), Office of the Speaker of the House of Commons, Parliament of Canada (2018–2018)

    Formerly Administrative Assistant, Office of the Speaker of the House of Commons, Parliament of Canada (2017–2018)

Institutions they may lobby: Agriculture and Agri-Food Canada (AAFC), Canada Revenue Agency (CRA), Canadian Institutes of Health Research (CIHR), Canadian International Trade Tribunal (CITT), Competition Tribunal (CT), Employment and Social Development Canada (ESDC), Environment and Climate Change Canada (ECCC), Finance Canada (FIN), Fisheries and Oceans Canada (DFO), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Justice Canada (JC), National Defence (DND), National Research Council (NRC), Natural Resources Canada (NRCan), Natural Sciences and Engineering Research Council (NSERC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Senate of Canada, Statistics Canada (StatCan), Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)

What they're lobbying on (23)
  • Canada's Drug Agency policies as it relates to reimbursement recommendation decision-making process and framework
  • Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
  • Federal policies that relate to possible models of pharmacare
  • Federal Buy Canadian Procurement Policy as it relates to government drug procurement practices and the implications for the biopharmaceutical industry
  • Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
  • Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
  • National Strategy for Drugs for Rare Diseases
  • World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility"
  • World Intellectual Property Organization (WIPO) issues concerning the biopharmaceutical industry
  • World Health Organization (WHO) issues concerning the biopharmaceutical industry
  • Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
  • Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
  • Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
  • Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
  • Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
  • Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
  • Income Tax Act as it relates to biopharmaceutical products
  • Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry
  • Free trade agreements as they relate to the biopharmaceutical industry
  • Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals
  • Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
  • Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
  • Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry

Registration 957857-371-135. Look it up in the official Registry

Reported meetings

Spreadsheet

Filed by Bettina Hamelin (157), Pamela Fralick (85), David Renwick (37).

  • Reported by Bettina Hamelin · In-house (organization)

    Free trade agreements as they relate to the biopharmaceutical industry Read more

    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes

    Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry

    Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

    Proposed pharmacare legislation related to any future national pharmacare program

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    Free trade agreements as they relate to the biopharmaceutical industry Read more

    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

    Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry

    Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework

    Proposed pharmacare legislation related to any future national pharmacare program

    Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    • Tony Loffreda · Senator, Senate of Canada
    Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry Read more

    Proposed pharmacare legislation related to any future national pharmacare program

    Free trade agreements as they relate to the biopharmaceutical industry

    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more

    Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry

    Proposed pharmacare legislation related to any future national pharmacare program

    Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework

    Free trade agreements as they relate to the biopharmaceutical industry

    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    Free trade agreements as they relate to the biopharmaceutical industry Read more

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

    Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)

    Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products Read more

    Free trade agreements as they relate to the biopharmaceutical industry

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

    Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    Free trade agreements as they relate to the biopharmaceutical industry Read more

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

    Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)

    Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    Free trade agreements as they relate to the biopharmaceutical industry Read more

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

    Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)

    Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB) Read more

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

    Free trade agreements as they relate to the biopharmaceutical industry

    Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    • Gary Xie · Senior Policy Advisor to the Secretary of State, International Development, Global Affairs Canada (GAC)
    Free trade agreements as they relate to the biopharmaceutical industry Read more

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Read more

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

    Free trade agreements as they relate to the biopharmaceutical industry

    Proposed pharmacare legislation related to any future national pharmacare program

    Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more

    Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)

    Free trade agreements as they relate to the biopharmaceutical industry

    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    • Paul Hébert · President, Canadian Institutes of Health Research (CIHR)
    Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    • Lisa Xie · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    Free trade agreements as they relate to the biopharmaceutical industry Read more

    Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    • Matthew Hall · Senior Policy Advisor, Prime Minister's Office (PMO)
    Free trade agreements as they relate to the biopharmaceutical industry Read more

    Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    • Miro Froehlich · Director of Policy, for Minister responsible for Canada-U.S. Trade, Intergovernmental Affairs and One Canadian Economy, Privy Council Office (PCO)
    • Galen Richardson · Senior Advisor, Stakeholder Relations for Minister responsible for Canada-U.S. Trade, Intergovernmental Affairs and One Canadian, Privy Council Office (PCO)
    Free trade agreements as they relate to the biopharmaceutical industry Read more

    Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    Proposed pharmacare legislation related to any future national pharmacare program Read more

    Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    • Greg Orencsak · Deputy Minister of Health, Health Canada (HC)
    Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry Read more

    Free trade agreements as they relate to the biopharmaceutical industry

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    • Mélanie Joly · Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, Innovation, Science and Economic Development Canada (ISED)
    Free trade agreements as they relate to the biopharmaceutical industry

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    • Jay Allen · Minister Economic, Global Affairs Canada (GAC)
    Free trade agreements as they relate to the biopharmaceutical industry Read more

    Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    Free trade agreements as they relate to the biopharmaceutical industry

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    • Anie Perrault · Acting Chairperson, Patented Medicine Prices Review Board (PMPRB)
    Free trade agreements as they relate to the biopharmaceutical industry Read more

    Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)

    Official report

  • Reported by Bettina Hamelin · In-house (organization)

    • Philip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    Free trade agreements as they relate to the biopharmaceutical industry

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.